Idorsia Ltd IDRSF
4.20 USD -0.50 (-10.64%)
Regular-session close
4.40 Day range 4.40
3.91 52-week range 8.19
- YTD
- -20.00%
- 1 year
- +7.42%
News
seekingalpha.com Idorsia Ltd (IDRSF) Shareholder/Analyst Call Transcript Idorsia Ltd (IDRSF) Shareholder/Analyst Call Transcript
seekingalpha.com Idorsia Ltd (IDRSF) Q2 2026 Earnings Call Transcript Idorsia Ltd (IDRSF) Q2 2026 Earnings Call Transcript
globenewswire.com Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon Ad hoc announcement pursuant to Art. 53 LR Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing New…
globenewswire.com Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology Allschwil, Switzerland – June 1, 2026 Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in…
globenewswire.com New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension Allschwil, Switzerland – June 01, 2026 Idorsia Ltd (SIX: IDIA) announces new analyses from the Phase 3 PRECISION study demonstrating that aprocitentan, Idorsia's dual endothelin receptor antagonist,…
globenewswire.com Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026 Allschwil, Switzerland – May 6, 2026 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the…
globenewswire.com Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next steps Co-promotion of QUVIVIQ is…
globenewswire.com Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders Allschwil, Switzerland – April 10, 2026 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The…
globenewswire.com Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development Allschwil, Switzerland – April 9, 2026 Idorsia Ltd (SIX: IDIA) announces the appointment of Dr Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) & Head of Global Clinical…
seekingalpha.com Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript
globenewswire.com Idorsia announces the nomination of three candidates for election to the Board of Directors Allschwil, Switzerland – March 24, 2026 Idorsia Ltd (SIX: IDIA) announces that the Board of Directors will propose three candidates for election to the Board at the upcoming Annual General Meeting of…
globenewswire.com Idorsia announces management change Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 16, 2026 Idorsia Ltd (SIX: IDIA) announces that Dr Srishti Gupta and the Board of Idorsia have mutually agreed that Srishti…
globenewswire.com Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink Allschwil, Switzerland – March 10, 2026 Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Pharmalink Drug Store L.L.C for the distribution and commercialization of QUVIVIQ™…
seekingalpha.com Idorsia Ltd (IDRSF) Q4 2025 Earnings Call Transcript Idorsia Ltd (IDRSF) Q4 2025 Earnings Call Transcript
globenewswire.com Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026 Ad hoc announcement pursuant to Art. 53 LR Idorsia delivers on its upgraded 2025 guidance, with strong QUVIVIQ sales growth, disciplined investment, and a significantly improved bottom line.
globenewswire.com Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call Idorsia will publish its Full Year 2025 Financial Reporting on Thursday February 26, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day.
globenewswire.com Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium Allschwil, Switzerland – January 30, 2026 Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual…
globenewswire.com Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026 Idorsia…
seekingalpha.com Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
globenewswire.com Idorsia to present at J.P. Morgan 2026 Healthcare Conference Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare…
